Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Other Events

Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Other Events

Story continues below

Item 8.01 Other Events

On March20, 2017, Esperion Therapeutics,Inc. issued a press
release titled, Esperion Announces FDA Confirmation Regarding
Regulatory Pathway to Approval for an LDL-C Lowering Indication
for Bempedoic Acid (the Press Release). A copy of the Press
Release is filed herewith as Exhibit99.1 and is incorporated
herein by reference.

Item 9.01 Financial Statements and Exhibits.





Press Release dated March20, 2017.


About Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Recent Trading Information

Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed its last trading session down -5.98 at 23.67 with 9,486,087 shares trading hands.

An ad to help with our costs